Trial Profile
Investigation on Efficacy and Safety of Apixaban in Japanese Elderly Patients: Investigator-Initiated Multicenter Prospective Cohort Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms J-ELD-AF-CVI-ARO5
- 01 Aug 2022 Results assessing the association of this body weight category with clinical outcomes in elderly AF patients receiving apixaban published in the Cardiovascular Drugs and Therapy
- 01 Sep 2020 Results (n=3015) of sub-group analysis from three subgroups divided based on creatinine clearance in elderly atrial fibrillation patients receiving apixaban presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology
- 01 Sep 2020 Results (N=3015) evaluating the distribution of blood apixaban concentration and its relationship with clinical outcomes presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology